Your browser doesn't support javascript.
loading
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
Hatlen, Megan A; Schmidt-Kittler, Oleg; Sherwin, Cori Ann; Rozsahegyi, Emily; Rubin, Nooreen; Sheets, Michael P; Kim, Joseph L; Miduturu, Chandrasekhar; Bifulco, Neil; Brooijmans, Natasja; Shi, Hongliang; Guzi, Timothy; Boral, Andy; Lengauer, Christoph; Dorsch, Marion; Kim, Richard D; Kang, Yoon-Koo; Wolf, Beni B; Hoeflich, Klaus P.
Affiliation
  • Hatlen MA; Blueprint Medicines Corporation, Cambridge, Massachusetts.
  • Schmidt-Kittler O; Blueprint Medicines Corporation, Cambridge, Massachusetts.
  • Sherwin CA; Blueprint Medicines Corporation, Cambridge, Massachusetts.
  • Rozsahegyi E; Blueprint Medicines Corporation, Cambridge, Massachusetts.
  • Rubin N; Blueprint Medicines Corporation, Cambridge, Massachusetts.
  • Sheets MP; Blueprint Medicines Corporation, Cambridge, Massachusetts.
  • Kim JL; Blueprint Medicines Corporation, Cambridge, Massachusetts.
  • Miduturu C; Blueprint Medicines Corporation, Cambridge, Massachusetts.
  • Bifulco N; Blueprint Medicines Corporation, Cambridge, Massachusetts.
  • Brooijmans N; Blueprint Medicines Corporation, Cambridge, Massachusetts.
  • Shi H; Blueprint Medicines Corporation, Cambridge, Massachusetts.
  • Guzi T; Blueprint Medicines Corporation, Cambridge, Massachusetts.
  • Boral A; Blueprint Medicines Corporation, Cambridge, Massachusetts.
  • Lengauer C; Blueprint Medicines Corporation, Cambridge, Massachusetts.
  • Dorsch M; Blueprint Medicines Corporation, Cambridge, Massachusetts.
  • Kim RD; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Kang YK; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Wolf BB; Blueprint Medicines Corporation, Cambridge, Massachusetts.
  • Hoeflich KP; Blueprint Medicines Corporation, Cambridge, Massachusetts. khoeflich@blueprintmedicines.com.
Cancer Discov ; 9(12): 1686-1695, 2019 12.
Article in En | MEDLINE | ID: mdl-31575540
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrans / Quinazolines / Carcinoma, Hepatocellular / Drug Resistance, Neoplasm / Receptor, Fibroblast Growth Factor, Type 4 / Liver Neoplasms Type of study: Prognostic_studies Limits: Aged80 / Animals / Female / Humans / Male / Middle aged Language: En Journal: Cancer Discov Year: 2019 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrans / Quinazolines / Carcinoma, Hepatocellular / Drug Resistance, Neoplasm / Receptor, Fibroblast Growth Factor, Type 4 / Liver Neoplasms Type of study: Prognostic_studies Limits: Aged80 / Animals / Female / Humans / Male / Middle aged Language: En Journal: Cancer Discov Year: 2019 Document type: Article Country of publication: